This session will cover some new data regarding treatment of type 2 diabetes: the GRADE study, SURPASS phase 3 program, the STEP program for treatment of obesity. It will also provide an update on studies using SGLT2 inhibitors and GLP 1 receptor agonists in people with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.
Given that 9 out of 10 people with diabetes also suffer from overweight or obesity, it is important for PCPs to take a holistic approach to treatment rather than solely a glucocentric approach. This activity helps you understand the benefits of weight loss as a key therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM) and the importance of early treatment intensification to improve long-term outcomes. You’ll also walk away from this session with a firm grasp of the role incretins play in the pathophysiology of T2DM, obesity, and other metabolic conditions and the latest clinical trial evidence behind incretin-based agents.